Hyperglycemia
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice.
|
20446767 |
2010 |
Impaired glucose tolerance
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice.
|
20446767 |
2010 |
Hyperglycemia, Postprandial
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice.
|
20446767 |
2010 |
Diffuse Large B-Cell Lymphoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.
|
16081686 |
2005 |
Dermatitis, Allergic Contact
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene transcripts as potential diagnostic markers for allergic contact dermatitis.
|
16033404 |
2005 |
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.
|
16081686 |
2005 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
And it has been demonstrated that peroxiredoxin 4 causally contributes to tumorigenesis, therapeutic resistance, metastasis, and recurrence of tumors.
|
31311441 |
2019 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
We previously reported that peroxiredoxin 4 (PRDX4), a secretory-type antioxidant enzyme, can protect against the development of various diseases, including potential malignancies.
|
30013444 |
2018 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.
|
25779674 |
2015 |
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrated that the expression of Prx IV was induced as cells became competent to synthesize immunoglobulin light chains, as observed by immunohistochemistry in tissue sections of B cell neoplasms and also by qPCR and Western blotting analyses in malignant B cell lines.
|
23737084 |
2013 |
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Reverse phase protein arrays verified that the overexpression of both PRDX3 and PRDX4 in tumor samples is negatively correlated with the presence of the TMPRSS2-ERG gene fusion.
|
22424448 |
2012 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our work reveals that the Srx-Prx IV axis is critical for lung cancer maintenance and metastasis, suggesting that targeting the Srx-Prx IV axis may provide unique effective strategies for cancer prevention and treatment.
|
21487000 |
2011 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Disruption or enhancement of the Srx-Prx IV axis leads respectively to reduction or acceleration of tumor growth and metastasis formation in vivo.
|
21487000 |
2011 |
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis revealed significantly higher levels of PRDX4 and P4HA2 in tumor cells than adjacent non-tumor epithelia (P < 0.0001 and P < 0.0001, respectively), and even higher expression in the 31 metastatic tumors of lymph nodes, compared to the corresponding primary tumors (P = 0.060 and P = 0.002, respectively).
|
21859152 |
2011 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Investigation of peroxiredoxin IV as a calpain-regulated pathway in cancer.
|
21187494 |
2010 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These results suggested that Prx IV involved in the 16alpha-OHE1-induced proliferation of MCF-7 cells has a proliferative effect and may be related to cancer development or progression.
|
18272409 |
2008 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Targeting of PRDX4 may represent a promising strategy to block HCC cell growth and metastasis.
|
31256347 |
2019 |
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, high expression of PRDX4 in the primary breast tumor was consistently associated with metastasis at 5 years.
|
25779674 |
2015 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.
|
25779674 |
2015 |
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemical analysis revealed significantly higher levels of PRDX4 and P4HA2 in tumor cells than adjacent non-tumor epithelia (P < 0.0001 and P < 0.0001, respectively), and even higher expression in the 31 metastatic tumors of lymph nodes, compared to the corresponding primary tumors (P = 0.060 and P = 0.002, respectively).
|
21859152 |
2011 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Disruption or enhancement of the Srx-Prx IV axis leads respectively to reduction or acceleration of tumor growth and metastasis formation in vivo.
|
21487000 |
2011 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Our work reveals that the Srx-Prx IV axis is critical for lung cancer maintenance and metastasis, suggesting that targeting the Srx-Prx IV axis may provide unique effective strategies for cancer prevention and treatment.
|
21487000 |
2011 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Investigation of peroxiredoxin IV as a calpain-regulated pathway in cancer.
|
21187494 |
2010 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
These results suggested that Prx IV involved in the 16alpha-OHE1-induced proliferation of MCF-7 cells has a proliferative effect and may be related to cancer development or progression.
|
18272409 |
2008 |
Adenocarcinoma of lung (disorder)
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The combination of the PRDX4 expression level with the EGFR mutation status was closely associated with the prognosis of patients with stage I LUAD.
|
31588184 |
2019 |